---
title: "Huahai Pharma Gets Registration Certificate for Olmesartan Medoxomil Tablets"
date: "2025-02-10 12:10:03"
summary: "Zhejiang Huahai Pharmaceutical's olmesartan medoxomil tablets received a drug registration certificate from the Chinese drug administration, according to a Shanghai Stock Exchange filing on Feb. 7. The pharmaceutical company invested about 7.5 million yuan for the research and development of the drug, which is mainly used for the treatment of..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Zhejiang Huahai Pharmaceutical's olmesartan medoxomil tablets received a drug registration certificate from the Chinese drug administration, according to a Shanghai Stock Exchange filing on Feb. 7.

The pharmaceutical company invested about 7.5 million yuan for the research and development of the drug, which is mainly used for the treatment of hypertension, the filing said.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250209:G2465390:0/)
